Erasca, Inc.

At Erasca, we're committed to discovering and developing therapies focused on helping patients with cancer. The U.S. FDA has granted Fast Track Designation to our potential best-in-class investigational pan #RAS molecular glue, ERAS-0015, to treat metastatic pancreatic adenocarcinoma. This marks an important stepping stone for the RAS solid tumor community. Fast Track Designation is designed to facilitate development and expedite the review of therapies for serious conditions with unmet medical need, reflecting the urgency of new treatment options for this patient population. We look forward to advancing our Phase 1 clinical trial and continuing our work to bring new treatment options for people living with #pancreaticcancer. Read more: https://lnkd.in/g_y6PxHC

Nearly a decade into our mission to erase cancer, we're proud to be featured in the San Diego Business Journal for the progress we've made toward completing that mission. Erasca's pipeline targets cancers driven by mutations of #RAS, one of the most commonly mutated genes in human cancer and, for over 30 years, considered largely undruggable. As our CEO Jonathan L. shared, there is growing excitement as the company transitions into a Phase 3 organization, building on the momentum already established this year. We're grateful to our team, our partners, and the patients who we work for. Read the full feature in the San Diego Business Journal (subscription required): https://lnkd.in/gHVyNyn6

Updated Phase 1 Data Reinforce Progress for ERAS-0015 in Pancreatic Cancer Updated data from our AURORAS-1 Phase 1 U.S. trial demonstrated a 57% unconfirmed objective response rate (uORR8wk) with ERAS-0015 monotherapy in second-line or later (2L+) KRAS G12X pancreatic ductal adenocarcinoma #PancreaticCancer, with favorable tolerability. (1,2) These results represent an important milestone in the ERAS-0015 development program and support our plans to advance the program toward potentially registration-enabling development in pancreatic and lung cancers. We are also advancing ERAS-0015 in combination with panitumumab, which has cleared its first dose-escalation cohort with no dose-limiting toxicities observed.(3) Separately, preliminary Phase 1 monotherapy data for ERAS-4001 from the BOREALIS-1 trial are expected in the second half of 2026. Read more here: https://lnkd.in/gsMAH-CS (1) Data cutoff (DCO) May 25, 2026 (2) The uORR8wk is the overall response rate (ORR) (confirmed and unconfirmed responses) for patients who received first dose of ERAS-0015 at least 8 weeks prior to the May 25, 2026 DCO (3) DCO July 6, 2026

We're thrilled to welcome Charles Fuchs, M.D., M.P.H. to Erasca as our new President of Research & Development. Charlie brings more than 30 years of leadership in oncology, spanning academic medicine, biopharma drug development, and patient care. Throughout his distinguished career, he has helped advance multiple approved cancer therapies and earned a reputation as one of the field's most respected scientific leaders. As we continue to advance our RAS-targeting franchise, Charlie's deep expertise, particularly in GI cancers, and his passion for translating scientific discoveries into new medicines will help shape the next chapter of Erasca's R&D strategy. Please join us in welcoming Charlie to the team as we continue our mission to discover, develop, and commercialize precision therapies for patients with RAS/MAPK pathway-driven cancers. Read the full announcement: https://lnkd.in/gt7xUEqB #Oncology #DrugDevelopment #PrecisionMedicine #CancerResearch #Biotech #Leadership

We are #hiring! Join us in our ambitious goal to #erasecancer. Contact Guevara Rowand or Alison Tjosvold Milhous for more information, or apply here or at www.erasca.com.

We are #hiring. Contact Guevara Rowand or Nik Chetwyn for more information or apply here or at www.erasca.com and join us in our audacious goal to #erasecancer.

We are #hiring! Join us in our audacious goal to #erasecancer. Contact Guevara Rowand for more information or apply here or at www.erasca.com

We are #hiring! Join us in our audacious goal to #erasecancer. Contact Guevara Rowand or Susan Spooner for more information or apply here or at www.erasca.com

Today we announced updated preliminary Phase 1 data for our potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors, including encouraging monotherapy responses in 2L+ KRAS G12X pancreatic cancer and early combination potential with panitumumab. Potentially registration-enabling plans for ERAS-0015 are advancing. Additional highlights include timing for ERAS-0015 monotherapy and combination data (expected 1H 2027), plus plans to initiate pivotal trials in #lungcancer and #pancreaticcancer over 2027 and into 2028. For additional details, read the press release here: https://lnkd.in/gvEBFPzQ

For decades, RAS was considered one of oncology’s most elusive targets. Today, advances in science and technology are helping unlock new possibilities for patients with RAS-driven cancers. In a recent interview with SurvivorNet at #ASCO2026, Erasca Chief Medical Officer Dr. Shannon Morris discussed the remarkable progress being made across the RAS field and the potential impact for patients with cancers such as pancreatic, colorectal, and lung cancer. At Erasca, we're proud to be advancing research focused on RAS/MAPK pathway-driven cancers. Thank you to SurvivorNet for highlighting this important conversation. https://lnkd.in/g3UMMJDE #Oncology #CancerResearch #PrecisionMedicine #RAS #Biotech #Erasca